Back

Prognostic impact of post-procedural low-molecular-weight heparin in high-bleeding risk patients undergoing pci for acute myocardial infarction

29 August 2026 (13:15 - 14:00)
Organised by: Logo
Congress Presentation Part of: Risk and benefits of antithrombotic drugs Anticoagulants ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Shao Qiang Qin

2nd Hospital of Tianjin Medical University, Tianjin (China)

5 More presentations in this session

Presentation thumbnail
Non-vitamin K antagonist oral anticoagulants versus warfarin and the risk of cataract in patients with atrial fibrillation: A real-world cohort study
Doctor S. Lin (Hualien, TW)
Abstract Slides
Presentation thumbnail
External validation of novel bleeding risk scores, ARC-HBR and PRECISE-HBR, in 5116 consecutive ACS patients in clinical practice
Professor A. Khand (Liverpool, GB)
Abstract Slides
Presentation thumbnail
Impact of recurrent venous thromboembolism and major bleeding events on subsequent mortality in patients with and without active cancer: Insights from the COMMAND VTE Registry-2
Doctor S. Kobayashi (Tsu, JP)
Abstract Slides
Presentation thumbnail
Single versus dual antiplatelet therapy after transcatheter aortic valve implantation in patients without an indication for anticoagulation: a systematic review and meta-analysis
Doctor C. Sanchez Serrano (Ciudad De Mexico, MX)
Abstract Slides
Presentation thumbnail
Concomitant antiplatelet therapy in anticoagulated TAVI patients with atrial fibrillation: impact of sex on bleeding and ischaemic events in ENVISAGE-TAVI AF
Doctor G. Dangas (New York, US)
Abstract Slides

Access the full session

Session thumbnail
Risk and benefits of antithrombotic drugs

The Event

Event poster

ESC Congress 2026

29 August 2026 13:15 CET
You may be interested in
thumbnail
Congress Presentation
Implications of ESC-high tthrombotic risk features and ARC-high bleeding risk criteria on clinical outcomes in all-comer patients undergoing PCI
29 August 2021
thumbnail
Congress Presentation
Prognostic impact of beta-blockers in AMI patients with mid-range left ventricular ejection fraction
21 May 2023
thumbnail
Congress Presentation
Direct oral anticoagulants versus low-molecular-weight heparin for thromboprophylaxis in cancer-related surgeries: a meta-analysis of efficacy and safety outcomes
31 August 2025
thumbnail
Congress Presentation
Efficacy and safety of upstream unfractionated heparin compared with downstream administration in ST-elevation myocardial infarction patients undergoing percutaneous coronary intervention.
8 March 2024

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources